Ascendis Pharma A/S Stock News

ADRs End Mostly Lower; Ascendis Pharma, Infosys Trade Actively Morningstar

The ADRs of Ascendis Pharma (ASND) have recorded the biggest intraday gain since August on Tuesday after Bank of America upgraded the Danish biotech citing “positive” results from a…

Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the likelihood of success of it

Following Ascendis Pharma’s (NASDAQ: ASND ) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the likelihood of success of its TCP has increased from 60% to 75%, according to BofA Securities. The Ascendis Pharma Analyst: Tazeen Ahmad upgraded the rating for Ascendis Pharma from Neutral to Buy, while raising … Full story available on Benzinga.com

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared

Upgrades For Turquoise Hill Resources Ltd (NYSE: TRQ ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared to $0.79 in the year-ago quarter. The stock has a 52-week-high of $26.73 and a 52-week-low of $9.75. At the end of the last trading period, Turquoise Hill Resources closed at $26.55. According to BMO Capital, the prior rating for Turquoise Hill Resources Ltd (NYSE: TRQ ) was changed from Underperform to Market Perform. In the fourth quarter, Turquoise Hill Resources showed an EPS of $0.78, compared to $0.79 from the year-ago quarter. The current stock performance of Turquoise Hill Resources shows a 52-week-high of $26.73 and a 52-week-low of $9.75. Moreover, at the end of the last trading period, the closing price was at $26.55. According to DA Davidson, the prior rating for Washington Federal Inc (NASDAQ: WAFD ) was changed from Neutral to Buy. Washington Federal earned $0.71 in the first quarter, compared to $0.51 in the year-ago quarter.

Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading. HC Wainwright & Co. lowered Gritstone

Ascendis Pharma A/S (NASDAQ: ASND ) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in which the body produces abnormally low levels of parathyroid hormone (PTH). 78.7% of TransCon PTH-treated patients achieved serum calcium levels in the normal range and independence from therapeutic levels of conventional therapy, compared to 4.8% for patients in the control … Full story available on Benzinga.com

Ascendis Pharma (ASND) said a phase 3 trial of TransCon PTH in adults with hypoparathyroidism ((HP)) met the main goal and all secondary objectives.HP is a condition in which the…

–  For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001).

– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001).

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Invest

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 6 1 0 0 Last

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis NuCana plc (NASDAQ: NCNA) s